CSL Limited
CSL
Rang in Aktien
#362
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aktienkurs
$138.58
Marktkapitalisierung
$66.50B
Veränderung (1 Tag)
0.72%
Veränderung (1 Jahr)
-2.29%
Land
AU
Handel CSL Limited (CSL)
Kategorie
Healthcare
P/B-Verhältnis für CSL Limited (CSL)
P/B-Verhältnis zum October 2026 TTM: 4.21
Laut den neuesten Finanzberichten und dem Aktienkurs von CSL Limited beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 4.21. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 5.43.
P/B-Verlauf für CSL Limited von 2000 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 4.21 | 6.80% |
| 2025 | 3.94 | -27.38% |
| 2024 | 5.43 | 44.67% |
| 2023 | 3.75 | -8.59% |
| 2022 | 4.11 | -64.62% |
| 2021 | 11.60 | -41.84% |
| 2020 | 19.95 | 52.81% |
| 2019 | 13.06 | -17.71% |
| 2018 | 15.87 | -20.12% |
| 2017 | 19.87 | 32.34% |
| 2016 | 15.01 | -0.22% |
| 2015 | 15.04 | 47.75% |
| 2014 | 10.18 | 1.25% |
| 2013 | 10.06 | 70.32% |
| 2012 | 5.91 | 28.39% |
| 2011 | 4.60 | -10.55% |
| 2010 | 5.14 | 17.45% |
| 2009 | 4.38 | -40.16% |
| 2008 | 7.31 | -12.44% |
| 2007 | 8.35 | 25.21% |
| 2006 | 6.67 | 58.64% |
| 2005 | 4.21 | 53.56% |
| 2004 | 2.74 | 23.37% |
| 2003 | 2.22 | -67.73% |
| 2002 | 6.88 | -56.70% |
| 2001 | 15.89 | 71.69% |
| 2000 | 9.25 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | 48.55% |
US
|
|
| 13.2547 | 214.99% |
US
|
|
| - | - |
CH
|
|
| 6.1824 | 46.92% |
NL
|
|
| 3.2932 | -21.74% |
BE
|
